Safety of recombinant activated factor VII in randomized clinical trials
- PMID: 21047223
- DOI: 10.1056/NEJMoa1006221
Safety of recombinant activated factor VII in randomized clinical trials
Erratum in
- N Engl J Med. 2011 Nov 17;365(20):1944
Abstract
Background: The use of recombinant activated factor VII (rFVIIa) on an off-label basis to treat life-threatening bleeding has been associated with a perceived increased risk of thromboembolic complications. However, data from placebo-controlled trials are needed to properly assess the thromboembolic risk. To address this issue, we evaluated the rate of thromboembolic events in all published randomized, placebo-controlled trials of rFVIIa used on an off-label basis.
Methods: We analyzed data from 35 randomized clinical trials (26 studies involving patients and 9 studies involving healthy volunteers) to determine the frequency of thromboembolic events. The data were pooled with the use of random-effects models to calculate the odds ratios and 95% confidence intervals.
Results: Among 4468 subjects (4119 patients and 349 healthy volunteers), 401 [corrected] had thromboembolic events (9.0%). [corrected] Rates of arterial thromboembolic events among all 4468 subjects were higher among those who received rFVIIa than among those who received placebo (5.5% vs. 3.2%, P=0.003). Rates of venous thromboembolic events were similar among subjects who received rFVIIa and those who received placebo (5.3% vs. 5.7%). Among subjects who received rFVIIa, 2.9% had coronary arterial thromboembolic events, as compared with 1.1% of those who received placebo (P=0.002). Rates of arterial thromboembolic events were higher among subjects who received rFVIIa than among subjects who received placebo, particularly among those who were 65 years of age or older (9.0% vs. 3.8%, P=0.003); the rates were especially high among subjects 75 years of age or older (10.8% vs. 4.1%, P=0.02).
Conclusions: In a large and comprehensive cohort of persons in placebo-controlled trials of rFVIIa, treatment with high doses of rFVIIa on an off-label basis significantly increased the risk of arterial but not venous thromboembolic events, especially among the elderly. (Funded by Novo Nordisk.).
Comment in
-
Off-label use of recombinant activated factor VII--safe or not safe?N Engl J Med. 2010 Nov 4;363(19):1853-4. doi: 10.1056/NEJMe1008857. N Engl J Med. 2010. PMID: 21047230 No abstract available.
-
Safety of recombinant activated factor VII in randomized clinical trials.N Engl J Med. 2011 Feb 10;364(6):575; author reply 575-6. doi: 10.1056/NEJMc1013591. N Engl J Med. 2011. PMID: 21306247 No abstract available.
-
Safety of recombinant activated factor VII in randomized clinical trials.N Engl J Med. 2011 Feb 10;364(6):575; author reply 575-6. doi: 10.1056/NEJMc1013591. N Engl J Med. 2011. PMID: 21306248 No abstract available.
-
Safety of recombinant activated factor VII in randomized clinical trials.N Engl J Med. 2011 Feb 10;364(6):574-5; author reply 575-6. doi: 10.1056/NEJMc1013591. N Engl J Med. 2011. PMID: 21306249 No abstract available.
-
Safety of recombinant activated factor VII in randomized clinical trials.N Engl J Med. 2011 Feb 10;364(6):574; author reply 575-6. doi: 10.1056/NEJMc1013591. N Engl J Med. 2011. PMID: 21306250 No abstract available.
-
Recombinant activated factor VII in chronic liver diseases: should we be afraid of thromboembolic events?J Hepatol. 2011 Aug;55(2):483-5. doi: 10.1016/j.jhep.2011.01.043. Epub 2011 Feb 22. J Hepatol. 2011. PMID: 21349297 No abstract available.
Similar articles
-
Off-label use of recombinant activated factor VII--safe or not safe?N Engl J Med. 2010 Nov 4;363(19):1853-4. doi: 10.1056/NEJMe1008857. N Engl J Med. 2010. PMID: 21047230 No abstract available.
-
Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage.Stroke. 2008 Mar;39(3):850-6. doi: 10.1161/STROKEAHA.107.493601. Epub 2008 Jan 31. Stroke. 2008. PMID: 18239180
-
Safety of recombinant activated factor VII in randomized clinical trials.N Engl J Med. 2011 Feb 10;364(6):575; author reply 575-6. doi: 10.1056/NEJMc1013591. N Engl J Med. 2011. PMID: 21306248 No abstract available.
-
The Judicious Use of Recombinant Factor VIIa.Semin Thromb Hemost. 2016 Mar;42(2):125-32. doi: 10.1055/s-0035-1569068. Epub 2016 Feb 2. Semin Thromb Hemost. 2016. PMID: 26838698 Review.
-
Review of the off-label use of recombinant activated factor VII in pediatric cardiac surgery patients.Anesth Analg. 2012 Aug;115(2):364-78. doi: 10.1213/ANE.0b013e31825aff10. Epub 2012 May 31. Anesth Analg. 2012. PMID: 22652310 Review.
Cited by
-
[Principles of perioperative coagulation management].Unfallchirurg. 2012 Apr;115(4):353-62; quiz 363. doi: 10.1007/s00113-012-2219-7. Unfallchirurg. 2012. PMID: 22476344 German.
-
Revolutionizing snakebite care with novel antivenoms: Breakthroughs and barriers.Heliyon. 2024 Jan 30;10(3):e25531. doi: 10.1016/j.heliyon.2024.e25531. eCollection 2024 Feb 15. Heliyon. 2024. PMID: 38333815 Free PMC article. Review.
-
Local pulmonary administration of factor VIIa (rFVIIa) in diffuse alveolar hemorrhage (DAH) - a review of a new treatment paradigm.Biologics. 2012;6:37-46. doi: 10.2147/BTT.S25507. Epub 2012 Mar 6. Biologics. 2012. PMID: 22419859 Free PMC article.
-
Massive Bleeding and Massive Transfusion.Transfus Med Hemother. 2012 Apr;39(2):73-84. doi: 10.1159/000337250. Epub 2012 Mar 12. Transfus Med Hemother. 2012. PMID: 22670125 Free PMC article.
-
Alternatives to blood transfusion.Lancet. 2013 May 25;381(9880):1855-65. doi: 10.1016/S0140-6736(13)60808-9. Lancet. 2013. PMID: 23706802 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical